Floatz logo

FLUTICASONE

Recurrent Ovarian Epithelial Cancer

Barbara Ann Karmanos Cancer InstituteSmall moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Recurrent Ovarian Epithelial Cancer cohort.

Asset / SponsorPhaseRating
Ziv-Aflibercept
National Cancer Institute (NCI)
Phase 2BB
Ixabepilone
Yale University
Phase 2BB
Temsirolimus
University of Southern California
Phase 2BB
TRASTUZUMAB
OHSU Knight Cancer Institute
Phase 2BB
Triapine
National Cancer Institute (NCI)
Phase 2BB

View all 39 →

Same molecule, other indications

FLUTICASONE is also rated in:

Unspecified Adult Solid Tumor, Protocol SpecificDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Adult Acute Myeloid LeukemiaDormant
BBB
Indicative ·
73 / 100
View asset →
Chronic Phase Chronic Myelogenous LeukemiaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →